Patients Sex (% male) Median age at  the first observation (IQRa) Median Nadir %CD4+ (IQRa) HIV viral load Median (range) % ARVb
Long Term Non-Progressor 26 (22.8%) 23.1% 5.42 (1.50-10.29) 28.5% (25.0-32.0) 400 (50-2500) 0.0
Slow Progressor 9 (7.9%) 88.9% 5.51 (4.51-7.20) 23.0% (19-25) 2300 (50-30000) 0.0
Fast Progressor 23 (20.2%) 60.9% 3.97 (2.10-6.68) 13% (9-17) 73000 (5280-500000) 68.2
Uncertain 56 (49.1%) 57.1% 1.79 (1.32-28.88) 21.5% (17-34) 14500 (400-270000) 100.0
aIQR Inter-quartile range.
b % of patients which started antiretroviral therapy.
Table 1: Demographic, immunological and therapeutic characteristics of the study groups classified according clinical progression.